MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $29.74 | Prev. Close $28.49 | Circuit Range N/A |
Day Range $29.47 - $29.99 | Year Range $9.38 - $44.77 | Volume 9,951 |
Average Traded $29.75 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $29.74 | $30.23 | +0.00% |
30-Apr-26 | $29.74 | $30.23 | +6.12% |
29-Apr-26 | $28.70 | $28.49 | -1.89% |
28-Apr-26 | $32.13 | $29.04 | -9.32% |
27-Apr-26 | $32.49 | $32.02 | +0.05% |
24-Apr-26 | $32.52 | $32.01 | -4.05% |
23-Apr-26 | $33.64 | $33.36 | -0.71% |